3 Numbers That Should Grab Your Attention in Merck's Q1 Earnings

3 Numbers That Should Grab Your Attention in Merck's Q1 Earnings

Most of the headlines you’ll see about Merck‘s (NYSE:MRK) first-quarter results focus on the company’s better-than-expected earnings and lower-than-expected revenue. It’s true that Merck did report Q1 adjusted earnings per share (EPS) of $1.05, which was higher than the $1.00 adjusted EPS Wall Street expected. And it’s true that the drugmaker’s Q1 revenue of $10 […]

The latest look at FDA's breakthrough designation finds no benefits from cancer meds

The latest look at FDA's breakthrough designation finds no benefits from cancer meds

T he idea of a breakthrough therapy was promoted to speed approvals of medicines that held promise for treating a life-threatening disease and demonstrated substantial improvement over existing drugs. However, a new study finds that, while cancer drugs considered to be breakthroughs were approved more quickly, they were not safer, more novel, or more effective […]

Vertex Pharmaceuticals Heads Toward An Important Tipping Point

Vertex Pharmaceuticals Heads Toward An Important Tipping Point

Introduction – Vertex as focused drug developer Many years of work and focus have led Vertex Pharmaceuticals (VRTX) toward what could be a truly solid, strong growth story. There are valuation issues, discussed later in the article. After years of frustration, VRTX is building out a franchise of interlocking drug combinations that are the first […]

Merck's Dangerous Keytruda Success

Merck's Dangerous Keytruda Success

Is it possible for things to go too well for a drugmaker’s most important franchise? That’s an important question for Merck & Co. Inc. It announced first-quarter earnings Tuesday, and immune-boosting cancer drug Keytruda was the star. The drug’s sales more than doubled from the same period last year, and helped prompt Merck to boost its full-year earnings and sales guidance.  […]

Saddled with sluggish sales, Regeneron and Sanofi slash the cost of cholesterol-lowering drug

Saddled with sluggish sales, Regeneron and Sanofi slash the cost of cholesterol-lowering drug

F rustrated by tepid sales and practical stumbling blocks, Regeneron and Sanofi are offering a huge discount on their treatment for bad cholesterol in exchange for a promise that health care’s biggest middleman will make it easier for patients to actually get the drug. Starting in July, the two companies will sell their cholesterol-lowering drug Praluent, […]

Experts propose improving clinical trials for lupus

Experts propose improving clinical trials for lupus

An Oklahoma Medical Research Foundation physician-scientist is spearheading a call for transformative changes in clinical trials for new lupus drugs. In a new paper, Dr. Joan Merrill led a large team of lupus specialists and treatment developers to detail approaches that could lead to new and effective drugs reaching hospitals and clinics. “In a nutshell, […]

India's drug regulatory force conducts third round of raids on manufacturers

India's drug regulatory force conducts third round of raids on manufacturers

India’s drug regulatory force, the Central Drugs Standards Control Organization, pulled off a third round of raids on drug facilities that were manufacturing products without approval. In the latest round of raids, the agency focused on manufacturing firms in Sikkim that resulted in the cancellation of one license and suspension of another, The Wire reported. […]

Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo …

Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo …

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it has entered into an agreement with Thermo Fisher Scientific to leverage the Oncomine™ Dx Target Test as a companion diagnostic for Spectrum’s novel […]